Weave | February 09, 2021
Weave, a well-known and a fastest growing tech company announced a sophisticated patient communication and engagement platform, which is called Weave Unify. This is a multi-location service and created specifically for the same business.
Weave, a complete business toolbox for service-based businesses company, has created weave unify to empower in healthcare business in multiple locations by leveraging both parties’ schedules, patient bases, to and call handling staff to improve communications, streamline operations, increase revenue, and provide personalized and modernized patient care across the globe.
"For healthcare professionals, it is very difficult to attract, efficiently communicate, and engage with the patients, and this turns to be even more complex as a business functions multiple practices across offices in different locations," said Weave, CEO, Roy Banks. "Weave Unify makes dealings in different locations to switch each other's professionals and strengths to benefit grow the business more rapidly and competently, deliver healthier brand experiences, all while decreasing operational costs."
A recent survey among 300 healthcare business operators and owners in multi locations, multi-location practices that often cross-schedule patients are 63% more expected to constantly have a complete schedule, serving to maximize every healthcare specialist's time.
On February 11, Weave is holding a webinar with Dr. Eric Roman, who is a practicing dentist. The webinar is on the ways healthcare businesses have to rethink the communication and growth strategy in the year, 2021.
Weave Unify, the latest adding to Weave's rising set of healthcare business solutions, includes various solutions for email marketing, payment processing, and patient communications and experiences to brand healthcare practices profitable and more efficient.
Weave is a complete business toolbox provider for service-based businesses. With weave’s unique integration of software and hardware, it helps to simplify and streamline bushes growth, communication and retention across the various stages of customer journey. Weave, with more than 20,000 customers, was the first company to join Y Combinator. The company has received many awards, such as Forbes 2020 and 2019 Cloud 100 and Fortune 100 Best Companies 2019.
DeepIntent | April 07, 2021
DeepIntent, the leading healthcare marketing technology company built to influence patient health and business outcomes, today announced DeepIntent Outcomes, which uses real-world clinical evidence to significantly boost script lift attributed to digital advertising. DeepIntent Outcomes, which is built into its Healthcare Demand-Side Platform (DSP), allows advertisers to measure and automatically optimize live promotions based on script performance from pharmaceutical claims data that is updated regularly.
DeepIntent Outcomes assists healthcare marketers in solving today's common barriers, such as data silos, the use of multiple channels, and delayed reporting. DeepIntent Outcomes enables marketers to use script performance to reduce waste, improve marketing mix in-flight and:
Plan their strategies focused on insights into patients' and providers' in-market behaviors.
Enable their media plans for all devices via a single platform;
Monitor the effects of each campaign in real-time
Optimize campaign efficiency regularly by automatically modifying creative, reach, frequency, publishers, pricing, and bidding strategy.
DeepIntent Outcomes promotes the ability to measure the combined impact of patient and provider advertisement on script lift as one of the strategic use cases. DeepIntent Outcomes partnered with Publicis Health Media to coordinate and measure ad exposures to patients and caregivers with one of their leading pharmaceutical clients. Through this new platform, their client's script lift has increased by an average of 10-35 %.
Through its collaboration with Komodo Health, DeepIntent Outcomes has access to the industry's most comprehensive, transparent, trusted, and verified healthcare data set, as well as the fastest pharmaceutical data refresh. DeepIntent's healthcare identification graph sees 75% of healthcare providers every day and 86% every month, with a 25% higher overall audience quality for patient campaigns. The combination of these two solutions provides previously unseen capabilities in the pharmaceutical market. DeepIntent was named Best-Buy Side Programmatic Platform by Digiday in 2020, beating out rivals such as Xandr and Verizon Media.
DeepIntent, founded by former Memorial Sloan Kettering data scientists, connects healthcare companies with patients and providers through all devices through proprietary data, media collaborations, and integrations. DeepIntent is seen to increase script lift while enhancing patients' quality of life from across the board, from campaign planning to audience targeting to measuring and maximizing. Its Healthcare Marketing Platform enables marketers at seven of the top ten pharmaceutical companies and major healthcare advertising agencies to have a direct impact on health and business outcomes.
Invitae | September 07, 2021
Invitae, a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by a16z, Section 32 and Verily, Ciitizen is working to build a global platform to help patients collect, organize, store and share their medical records digitally. The acquisition would enhance Invitae's platform by providing patients an easy-to-use, centralized hub for their genomic and clinical information, which together comprise a powerful dataset with the potential to drive research and improve healthcare decision making.
"Invitae is relentlessly pursuing a day when genetics is used routinely to improve healthcare for billions of people around the globe. We believe combining Ciitizen's state-of-the-art, transparent and patient-consented platform with our technologies and services will accelerate our evolution into a genome information company that informs healthcare throughout one's life. This would give us the ability to engage patients, create an innovative patient-centered data ecosystem and deliver better outcomes for everyone. Invitae views the acquisition of Ciitizen as an important part of its strategy to be the industry leader across the genetic testing, software and health information technology spaces," said Sean George, Ph.D., co-founder and CEO of Invitae.
"Ciitizen has already helped patients take ownership of their medical records to optimize therapy for themselves and contribute their data towards a variety of goals, including research on rare diseases," said Anil Sethi, CEO and founder of Ciitizen. "Patients leave a breadcrumb trail of records behind them, and we believe access to this real-world data is key to personalized therapeutics in the future. The combination of lifelong health history together with Invitae's world-class genetic and data services would enable a digital ecosystem of personalized services for each patient. Democratization of patient-consented data is expected to improve outcomes by providing access to third-parties for whom the patient has granted consent. Unlike many health data companies, we operate on the premise that it's the patient's data, not ours."
Dr. George continued, "Genomics is currently a laboratory testing-based industry, but in the future it will look very much like an information industry. Developing an open-ended patient-centric platform of genomic, clinical and reported outcomes creates a thriving and purposeful network that truly advances healthcare. Patient control is the big differentiator at Ciitizen and at Invitae; and we believe combining forces is the right strategy for our businesses going forward."
Empowering patients to combine their genomic and clinical information to improve clinical care
Invitae is working to aggregate results from the world's genetic tests into a single, easy-to-use service that makes genetic information accessible to all who can benefit from it - always with patient consent. Over the past five years, Invitae has completed 13 acquisitions that have expanded its testing menu, lowered the cost of its tests, improved its customer experience and enhanced its ability to attract partners. Invitae raised more than $1.4 billion since the beginning of 2021, in part to identify and acquire key assets that bring the company closer to delivering on its vision.
The addition of Ciitizen is expected to empower Invitae to more quickly extend its platform, adding a complementary patient service that streamlines the process of collecting and organizing health information from any source and uses machine learning to transform the unstructured (and largely untapped) health information to enable better care decisions, find clinical trials, and power research using real-world evidence. In addition, as the use of Invitae testing and the Ciitizen service expands, third-party access to consented genomic and other clinical data can be democratized to power a variety of applications that can enhance Invitae's business and growth strategy.
Under the terms of the agreement, Invitae will acquire Ciitizen for approximately $325 million (subject to adjustment), consisting of (i) approximately $125 million in cash and (ii) approximately 7,070,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date). Invitae will also issue approximately $225 million in restricted stock units (RSUs) to new employees who join Invitae in connection with its acquisition of Ciitizen. These RSUs will be granted under Invitae's 2015 Stock Incentive Plan, which is being amended and restated to increase a pool of shares of Invitae common stock thereunder which is used exclusively for the grant of inducement awards in compliance with New York Stock Exchange Rule 303A.08 ("Rule 303A.08"). These RSUs have been approved by the Invitae Board of Directors and will be made as an inducement material to each employee entering into employment with Invitae in reliance on the employment inducement exemption under Rule 303A.08. These RSUs will cover up to a total of approximately 8,125,000 shares of Invitae common stock (based upon a trailing average closing price prior to the agreement date) and will vest in tranches of one-third upon each of the first, second and third anniversaries of the date of grant, subject to acceleration in the event of a termination without cause by Invitae or a termination with good reason by a recipient. A total of 99 recipients will receive these RSUs, and Anil Sethi, the CEO and founder of Ciitizen, will receive RSUs with respect to approximately 2,011,000 shares of Invitae common stock.
The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close this month.
Conference Call and Webcast today at 8:30 a.m. ET / 5:30 a.m. PT
Management will host a conference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT to discuss the transaction. To register for the conference call, please use the link below. Upon registering, each participant will be provided with call details and a registrant ID.
The live webcast of the call and slide deck may be accessed here or by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website.
Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices.
Ciitizen is a patient-centric consumer health technology platform that enables patients to collect, store and share their medical records in a single location. Ciitizen developed proprietary machine learning and AI technologies to abstract critical information from unstructured health records to advance the understanding of diseases, match patients with potentially life-saving clinical trials, and enable better care decisions. Ciitizen also provides valuable big data analytics and data quality technologies to the network of Health Information Exchanges (HIEs) to produce research-ready, regulatory-grade data within minutes, instead of hours or days, and ensure HIEs can comply with the Information Blocking regulations.